•  
  •  
  •  
  •  

2026-01-03 09:19:57

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Dixon Technologies India Ltd's subsidiaries granted approval by MeitY under ECMS
  • Adani Enterprises launches its 3rd public issue of NCDs of ₹1,000 crore, offering up to 8.90% per annum
  • KPI Green Energy Ltd's 92.15 MWp IPP Hybrid Power Project awarded by GUVNL begins supplying power ahead of schedule
  • Karthikeyan Manickam is the New Chairman of ESAF Small Finance Bank
  • Nifty Surges Nearly 200 Points to Close at All-Time High on Broad-Based Buying

Keywords Selected:  MHRA

Stock Report

  • Relonchem Limited receives Marketing Authorization for its two products
  • Relonchem Limited receives Marketing Authorization for two of its products
  • Relonchem Limited receives Marketing Authorization for its products
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Biocon Biologics receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars
  • BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon® in the UK
  • Relonchem Limited receives Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA
  • CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA
  • Aarti Drugs Ltd's subsidiary receives CGMP certificate from UK MHRA
  • Relonchem Limited receives Marketing Authorization from UKMHRA for its products
  • UK Relonchem Ltd, receives Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets
  • Relonchem Limited receives UKMHRA Marketing Authorization for its products
  • Relonchem Ltd receives Marketing Authorisation for the product Levetiracetam Relonchem 100 mg/mL Oral Solution
  • Sentynl Therapeutics receives marketing authorization for NULIBRY® from the UK MHRA for treatment of MoCD Type A
  • Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide
  • Biocon is the first generics Company to obtain approval for diabetes drug, Liraglutide, in the U.K.
  • Biocon Biologics Receives MHRA, UK Approval for YESAFILI®, Biosimilar Aflibercept
  • UK MHRA renews GMP compliance of Kopran Ltd's two plants
  • Shilpa Medicare receives UK‐MHRA Approval for Betahistine Dihydrochloride Orodispersible Films, 24 mg
  • Lupin announces Successful Completion of UK MHRA Inspection of its Pithampur Facilities
  • Marksans Pharma Ltd announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
  • Lupin announces UK MHRA Approval of Lutio® for Treatment of COPD
  • Shilpa Medicare Limited, Unit VI, Bengaluru facility has been issued UK MHRA GMP
  • Brooks Steriscience Ltd recieves UK MHRA marketing authorization for Meropenem Injection

Latest Post

  • Dixon Technologies India Ltd's subsidiaries granted approval by MeitY under ECMS
  • Adani Enterprises launches its 3rd public issue of NCDs of ₹1,000 crore, offering up to 8.90% per annum
  • KPI Green Energy Ltd's 92.15 MWp IPP Hybrid Power Project awarded by GUVNL begins supplying power ahead of schedule
  • Karthikeyan Manickam is the New Chairman of ESAF Small Finance Bank
  • Nifty Surges Nearly 200 Points to Close at All-Time High on Broad-Based Buying


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025